Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q1 2017 · 10-Q
Revenue$18.62K$18.62K+33.0% vs Q1 2016 Net Income-$524.16K-$524.16KN/M vs Q1 2016 EPS Diluted-$0.01-$0.01N/M vs Q1 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flow-$580,922N/M Margins · derivedGross margin-109.1%−100.4 pt vs Q1 2016
Operating margin-2558.1%+4169.3 pt vs Q1 2016
Net margin-2815.0%+3997.5 pt vs Q1 2016
ended Mar 31, 2017 · filed May 22, 2017 · 52 d after period end